Ebola Outbreak in Congo Escalates as Vaccination Campaign Begins Amid Record-Breaking Spread

Kinshasa, August 28, 2026: The Democratic Republic of Congo is facing an unprecedented Ebola emergency as the disease continues spreading across eastern parts of the country, putting enormous pressure on healthcare services and prompting authorities to launch an emergency vaccination campaign.

The outbreak is caused by the Bundibugyo virus, a less common Ebola species for which no vaccine has been specifically approved. Health authorities are therefore using an existing Ebola vaccine under special arrangements while researchers study whether it can provide protection against the current virus.

A Rapidly Expanding Health Emergency

The outbreak has become the largest Ebola outbreak ever recorded in the Democratic Republic of Congo.

According to the European Centre for Disease Prevention and Control, DRC reported 5,656 confirmed cases and 2,715 related deaths as of August 25, with more than 1,200 people having recovered. The figures remain subject to ongoing verification and data harmonisation.

The outbreak has expanded to six provinces, with Ituri remaining the principal centre of transmission.

The speed of the spread has alarmed international health agencies, which have warned that existing response operations need to be expanded substantially.

Vaccination Campaign Gets Underway

A major development came on August 27 when DRC officially began an Ebola vaccination campaign in Kisangani, the capital of Tshopo province.

Health workers and other frontline personnel are among the first people being vaccinated, along with individuals who have been in contact with Ebola patients.

More than 50,000 doses of the Ervebo vaccine have been made available, with additional doses expected as the campaign expands.

The campaign is unusual because Ervebo is approved for protection against Zaire ebolavirus rather than Bundibugyo virus.

Scientists hope that the relationship between the two viruses may allow the vaccine to provide some protection, but its effectiveness against Bundibugyo Ebola remains uncertain.

Clinical Research Becomes Part of the Response

The vaccination programme is also providing an opportunity to collect scientific evidence.

Of the 70,000 doses allocated for DRC, 20,000 have been designated for a Phase 3 clinical trial, while 50,000 are intended for frontline and healthcare workers under current recommendations.

Researchers will monitor vaccinated individuals to determine whether the vaccine reduces infections or severe disease.

The findings could become extremely important because future Bundibugyo outbreaks may require a dedicated preventive tool.

Why This Outbreak Is So Difficult to Control

Several factors are working against the response.

Many affected communities are located in regions experiencing armed conflict and insecurity. This can prevent health teams from reaching patients and makes surveillance more difficult.

Population displacement has also increased movement between communities.

People travelling for employment, trade and family reasons can unintentionally carry the virus into new areas before symptoms are recognized.

These circumstances have contributed to the geographical expansion of the outbreak.

Ituri Remains the Epicentre

Ituri province continues to account for the majority of confirmed infections and deaths.

The WHO has reported that the outbreak has affected dozens of health zones, with transmission remaining active across several provinces.

The scale of the outbreak means authorities must simultaneously investigate suspected cases, trace contacts, provide treatment, protect healthcare workers and maintain essential health services.

This requires enormous logistical resources.

Healthcare Workers Face Exceptional Risks

Medical workers are among the people most exposed to Ebola.

The WHO has reported confirmed infections and deaths among healthcare personnel during the current outbreak.

Healthcare facilities can become important points of transmission if infection-prevention procedures are difficult to maintain.

Protective equipment, training, laboratory testing and safe isolation facilities are therefore essential.

However, healthcare workers in some affected areas are also dealing with difficult working conditions, insecurity and disruptions to salary payments.

Community Trust Is Critical

Containing Ebola depends heavily on cooperation from local communities.

People must be willing to report symptoms, allow health workers to investigate contacts and follow isolation recommendations.

Misinformation can make these tasks considerably harder.

WHO and Africa CDC have repeatedly emphasized the importance of working with trusted community leaders rather than relying only on official announcements.

Building trust is particularly important in communities that have experienced years of conflict and limited access to government services.

The Outbreak Has Already Crossed Borders

The regional consequences of the crisis are also being closely monitored.

Uganda, which borders the DRC, successfully ended its own Bundibugyo Ebola outbreak after completing the required period without new locally transmitted cases.

However, WHO continues to warn that Uganda remains vulnerable to imported infections because transmission is still occurring in neighbouring DRC.

Other countries in the region are strengthening surveillance and preparedness at borders.

International Risk Remains Lower Than the Local Threat

Despite the seriousness of the outbreak, international health agencies have not recommended broad travel or trade restrictions.

WHO’s assessment indicates that the greatest risk remains concentrated in DRC and neighbouring countries with significant cross-border movement.

For countries farther away, the global risk is considered considerably lower.

This distinction is important because Ebola is not transmitted as easily as respiratory viruses such as influenza or COVID-19.

Transmission generally requires direct contact with the blood or bodily fluids of an infected person or contaminated materials.

Treatment and Early Detection Save Lives

There is currently no approved specific treatment for Bundibugyo Ebola.

However, supportive medical care can improve survival.

Rapid diagnosis, isolation, fluid management, treatment of complications and infection-control measures can all make a major difference.

Early detection is particularly important because people are not considered infectious before symptoms appear.

Once symptoms begin, however, the disease can progress rapidly.

Funding Shortages Add to the Challenge

The scale of the emergency has created a major demand for international funding.

WHO, Africa CDC and humanitarian organizations have called for additional resources to support surveillance, treatment, vaccination, laboratories, transportation and frontline workers.

Without sustained financing, response operations may struggle to keep pace with the speed of transmission.

The WHO has warned that a substantial expansion of the response is necessary to get ahead of the outbreak.

A Race Against Time

The central challenge for Congo is to reduce transmission faster than the virus can establish new chains of infection.

Vaccination, contact tracing, laboratory testing and community engagement must therefore operate simultaneously.

Any delay can allow an undetected infection to generate additional cases.

The experience of Uganda provides an encouraging example that rapid action can stop transmission. But Congo’s much larger outbreak, combined with insecurity and population movement, makes the task substantially more difficult.

What Happens Next?

The coming weeks will be crucial.

Authorities will closely monitor the vaccination programme, expand testing and treatment capacity and attempt to reach communities that remain difficult to access.

Researchers will also watch the clinical trial for evidence about whether Ervebo can protect against Bundibugyo virus.

If the vaccine provides meaningful protection, it could become an important additional tool against the current outbreak and future emergencies.

For now, however, the priority remains stopping transmission and protecting the people working on the front lines.

The Congo Ebola crisis has become a major test of international public-health cooperation. Its outcome will depend not only on medical technology, but also on security, funding, community trust and the ability of response teams to reach people before the virus reaches them.

Note: Ebola case and death figures are continuously revised as laboratory results, investigations and data reconciliation are completed. The figures cited above reflect the latest officially reported information available before publication.